Results 61 to 70 of about 8,545 (210)

Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2 [PDF]

, 2022
Three directly acting antivirals (DAAs) demonstrated substantial reduction in COVID-19 hospitalizations and deaths in clinical trials. However, these agents did not completely prevent severe illness and are associated with cases of rebound illness and ...
Aittokallio, Tero, Biering, Scott B., Gale, Michael, Herring, Shawn, Hoffmann, Markus, Hsiang, Tien-Ying, Ianevski, Aleksandr, Poehlmann, Stefan, Polyak, Stephen J., Schiffer, Joshua T., Wagoner, Jessica, White, Judith M., Xu, Shuang   +12 more
core   +2 more sources

Population-Based Propensity Score-Matched Analysis of Paxlovid and Molnupiravir Effectiveness in High-Risk COVID-19 Patients

International Journal of Infectious Diseases
Introduction: COVID-19 poses a severe threat to high-risk populations, such as the elderly and those with incomplete vaccination. Despite the availability of treatments like Paxlovid and Molnupiravir, their relative effectiveness in preventing severe ...
Dr Yi-hsuan Chen, Dr Cheng-Yi Lee, Dr Hao-Yuan Cheng, Mr. Yu-Neng Cheuh, Mr. Hung-Wei Kuo   +4 more
doaj   +1 more source

Differences in SARS‐CoV‐2 antigen persistence in individuals with systemic autoimmune rheumatic diseases compared to the general population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, Accepted Article.
Background Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post‐acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M.M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, RECOVER‐Adult   +18 more
wiley   +1 more source

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication [PDF]

, 2022
Funding Information: We thank Thorsten Wolff, Daniel Bourquain, Jessica Schulz, and Christian Mache from the Robert-Koch Institute and Martin Beer from the Friedrich Loeffler Institute (FLI) for providing isolates of SARS-CoV-2 variants.
Balkema-Buschmann, Anne, Blaurock, Claudia, Breithaupt, Angele, Dickmanns, Antje, Dobbelstein, Matthias, Eberlein, Valentina, Groß, Uwe, Grunwald, Thomas, Görlich, Dirk, Heinen, Natalie, Herrmann, Simon T., Issmail, Leila, Karrasch, Tim, Klopfleisch, Robert, Kohlhof, Hella, Müller, Thorsten, Peelen, Evelyn, Pfaender, Stephanie, Riek, Alexander, Sadeghi, Balal, Schreieck, Amelie, Speakman, John R., Stegmann, Kim M., Uhlig, Nadja, Vitt, Daniel   +24 more
core   +2 more sources

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in patients at high risk [PDF]

, 2023
Background Using a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable. Methods The impact of each drug was determined via comparisons
Antoniadou, Anastasia, Filippou, Dimitrios, Gaga, Mina, Gerolymatos, Gerasimos, Gkolfinopoulou, Kassiani, Gkova, Maria, Kostaki, Evangelia-Georgia, Kotanidou, Anastasia, Loukides, Stylianos, Mellou, Kassiani, Mossialos, Elias, Paraskevis, Dimitrios, Psalida, Naya, Saroglou, Georgios, Skoutelis, Athanasios, Thiraios, Eleftherios, Tsiodras, Sotirios, Zaoutis, Theoklis, Zografopoulos, Dimitrios   +18 more
core   +1 more source

Structural analysis of the flexibility of the Ubl2 domain within the papain‐like protease of SARS‐CoV‐2

Acta Crystallographica Section F, EarlyView.
The ubiquitin‐like domain 2 (Ubl2) of the SARS‐CoV‐2 virus is necessary for the stability and catalytic efficiency of its papain‐like protease (PLpro). Our crystallographic study reveals that the Ubl2 domain exhibits notable flexibility and can adopt a conformation that places itself away from the PLpro catalytic domain, representing a new conformation
Gian Luca Freiherr von Scholley, Martina Schaefer, Mark D. Tully, Marc-Andre Hograindleur, Montserrat Soler-López, Roman C. Hillig, Christoph Mueller-Dieckmann, Eaazhisai Kandiah   +7 more
wiley   +1 more source

Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study [PDF]

, 2023
Purpose: To investigate the clinical impact of three available antivirals for early COVID-19 treatment in a large real-life cohort. Methods: Between January and October 2022 all outpatients tested positive for SARS-CoV-2 referring to IRCCS S.
Bonazzetti C., Campoli C., Casarini M., Curti S., Gallo M., Giannella M., Malosso M., Marconi L., Marzolla D., Pascale R., Pasquini Z., Riccardi R., Riccucci D., Rinaldi M., Tazza B., Viale P., Zuppiroli A.   +16 more
core   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1604-1613, June 2026.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source

Fullerene Derivatives for Drug Delivery against COVID-19: A Molecular Dynamics Investigation of Dendro[60]fullerene as Nanocarrier of Molnupiravir

Nanomaterials, 2022
In this paper, a theoretical investigation is made regarding the possibility of using a water-soluble derivative of C60 as a drug delivery agent for treating Coronavirus disease 2019 (COVID-19).
Georgios I. Giannopoulos
doaj   +1 more source